News | January 06, 2026
PathoCare Holdings valued at $1.75 billion following major third-party tender offer
The company previously completed a $150 million venture investment, acquisition, and recapitalization
The company previously completed a $150 million venture investment, acquisition, and recapitalization
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
The company said it received notice on January 1 from the FDA’s Center for Veterinary Medicine that the funding will support its ongoing effectiveness study of Canalevia-CA1
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
India’s traditional medicine systems have also earned formal recognition in key bilateral trade agreements
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Subscribe To Our Newsletter & Stay Updated
